Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status.
deficient mismatch repair system
endometrial cancer
immune checkpoint inhibitors
type II
Journal
Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525
Informations de publication
Date de publication:
09 Apr 2023
09 Apr 2023
Historique:
received:
10
02
2023
revised:
04
04
2023
accepted:
06
04
2023
medline:
28
4
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
Type II endometrial cancer (EC) is responsible for most endometrial cancer-related deaths due to its aggressive nature, late-stage detection, and high tolerance to standard therapies. Thus, novel treatment strategies for type II EC are imperative. For patients with mismatch repair-deficient (dMMR) tumors, immunotherapy with immune checkpoint inhibitors represents a promising therapeutic strategy. However, the prevalence of dMMR tumors in type II EC patients remains unclear. In this study, using immunohistochemistry, we evaluated the expression of mismatch repair (MMR) proteins, tumor-infiltrating lymphocytes (CD8+), and immune checkpoint molecules (PD-L1) in 60 patients with type II EC (16, 5, 17, and 22 were endometrioid G3, serous, de-differentiated, and carcinosarcoma cases, respectively) to investigate the therapeutic effect of immune checkpoint inhibitors. Approximately 24 cases (40%) had a loss of MMR protein expression. The positivity rate of CD8+ (
Identifiants
pubmed: 37107907
pii: healthcare11081073
doi: 10.3390/healthcare11081073
pmc: PMC10137870
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Eur J Cancer. 2010 Oct;46(15):2788-98
pubmed: 20627535
Int J Mol Sci. 2019 Jul 31;20(15):
pubmed: 31370215
Int J Gynaecol Obstet. 2009 May;105(2):103-4
pubmed: 19367689
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
Cancer. 2008 Aug 15;113(4):733-42
pubmed: 18543306
N Engl J Med. 2022 Jun 23;386(25):2363-2376
pubmed: 35660797
Br J Cancer. 2006 Mar 13;94(5):642-6
pubmed: 16495918
PLoS One. 2019 Feb 27;14(2):e0212513
pubmed: 30811474
Cancer Res. 1998 Nov 15;58(22):5248-57
pubmed: 9823339
Gynecol Oncol. 1983 Feb;15(1):10-7
pubmed: 6822361
Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2965-70
pubmed: 25392179
J Clin Oncol. 2014 Jan 10;32(2):90-100
pubmed: 24323032
Lancet Oncol. 2005 Dec;6(12):961-71
pubmed: 16321764
Future Oncol. 2014 Dec;10(16):2561-8
pubmed: 25531045
J Clin Oncol. 2022 Aug 20;40(24):2735-2750
pubmed: 35649217
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
J Clin Oncol. 2005 Jan 20;23(3):609-18
pubmed: 15659508
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Clin Oncol. 2016 Sep 10;34(26):3119-25
pubmed: 27269937
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Oncol Rep. 2008 Mar;19(3):775-81
pubmed: 18288415
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Cancer Control. 2009 Jan;16(1):46-52
pubmed: 19078929
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
Br J Surg. 2017 Aug;104(9):1250-1259
pubmed: 28401534
Int J Mol Sci. 2019 Oct 16;20(20):
pubmed: 31623180
JCO Precis Oncol. 2017;2017:
pubmed: 29850653
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Clin Oncol. 2014 Apr 1;32(10):1020-30
pubmed: 24590637
Oncol Rep. 1999 Nov-Dec;6(6):1377-82
pubmed: 10523715
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Lancet Oncol. 2016 Oct;17(10):1374-1385
pubmed: 27592805
Gynecol Oncol. 2018 Apr;149(1):146-154
pubmed: 29496294
Cancer Sci. 2018 Dec;109(12):3993-4002
pubmed: 30447042
Histopathology. 2016 Aug;69(2):288-97
pubmed: 26799366
Oncotarget. 2017 Dec 31;9(5):5652-5664
pubmed: 29464025
Cancer Causes Control. 2010 Nov;21(11):1851-6
pubmed: 20628804
N Engl J Med. 2022 Feb 3;386(5):437-448
pubmed: 35045221
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Histopathology. 2013 Jan;62(1):111-23
pubmed: 23240673
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Gynecol Oncol. 2019 Sep;154(3):461-466
pubmed: 31257009
N Engl J Med. 2016 Jun 30;374(26):2542-52
pubmed: 27093365
Cancers (Basel). 2021 May 27;13(11):
pubmed: 34072037
Trends Cancer. 2016 Mar;2(3):121-133
pubmed: 28741532
Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S105-S143
pubmed: 29644661
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Biomolecules. 2022 Jul 26;12(8):
pubmed: 35892341
Expert Rev Clin Pharmacol. 2022 Jan;15(1):1-9
pubmed: 35184615
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
Clin Cancer Res. 2018 Dec 1;24(23):5939-5947
pubmed: 30068706
Nature. 2014 Nov 27;515(7528):558-62
pubmed: 25428503
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Lancet Oncol. 2017 May;18(5):599-610
pubmed: 28373005
J Clin Oncol. 2017 Jul 1;35(19):2117-2124
pubmed: 28375787
Int J Gynaecol Obstet. 2015 Oct;131 Suppl 2:S96-104
pubmed: 26433681
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Clin Cancer Res. 2011 Mar 15;17(6):1331-40
pubmed: 21266528
J Clin Oncol. 2016 Sep 1;34(25):3062-8
pubmed: 27325856
Beijing Da Xue Xue Bao Yi Xue Ban. 2006 Feb 18;38(1):62-5
pubmed: 16415969
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
Lancet. 2005 Aug 6-12;366(9484):491-505
pubmed: 16084259
Am J Surg Pathol. 2012 Feb;36(2):163-72
pubmed: 22189970